A sunny quarter before stormy times
15/05/25 -"Merck’s decision to provide detailed FY guidance was overshadowed by the significant impact of US President Trump’s actions. Consequently, expectations have shifted, and uncertainty has ..."
Pages
82
Language
English
Published on
15/05/25
You may also be interested by these reports :
15/05/25
Merck’s decision to provide detailed FY guidance was overshadowed by the significant impact of US President Trump’s actions. Consequently, ...
15/05/25
Sanofi’s share price is down c.15% since its March 2025 highs, largely owing to the US tariff and drug pricing uncertainty within the sector, ...
14/05/25
Q1 results came in much ahead of expectations, driven by robust momentum for Lundbeck’s four key products. Consequently, the management upgraded its ...
14/05/25
As reverters to the mean, Pharmas have been a waste of time since Covid (say 5 years), over 2 years, 1 year and ytd. This is computed on an ...